Tumor necrosis factor inhibitors for rheumatoid arthritis

被引：344
作者：
Scott, D. L. [1 ]
Kingsley, G. H.
机构：
[1] Kings Coll London, Kings Coll London Sch Med, Dept Rheumatol, London, England
[2] Kings Coll Hosp London, Dept Rheumatol, London, England
[3] Univ Hosp Lewisham, Dept Rheumatol, London, England
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 355卷 / 07期
关键词：
D O I：
10.1056/NEJMct055183
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rheumatoid arthritis developed in a 25-year-old woman, who was found to have a positive rheumatoid factor (150 IU per milliliter); she had no periarticular radiologic erosions or extraarticular disease. Oral methotrexate was started and incrementally increased to 20 mg weekly. Subsequently, sulfasalazine (Salazotyrin, Pharmacia; Azulfidine, Pfizer) was added and gradually increased to 2 g daily. Despite six months of combination therapy, she had 10 swollen and tender joints and an elevated erythrocyte sedimentation rate (54 mm per hour). Twelve months after onset, we were asked to evaluate her for possible tumor necrosis factor (TNF) inhibitor therapy. Copyright © 2006 Massachusetts Medical Society.
引用
收藏
页码：704 / 712
页数：9
相关论文
共 54 条
[1]   Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden [J].
Askling, J ;
Fored, CM ;
Brandt, L ;
Baecklund, E ;
Bertilsson, L ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Romanus, V ;
Klareskog, L ;
Feltelius, N .
ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :1986-1992
[2]   Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Baecklund, E ;
Brandt, L ;
Backlin, C ;
Ekbom, A ;
Sundström, C ;
Bertilsson, L ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L ;
Feltelius, N .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420
[3]   Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists [J].
Askling, J ;
Fored, CM ;
Brandt, L ;
Baecklund, E ;
Bertilsson, L ;
Feltelus, N ;
Cöster, L ;
Geborek, P ;
Jacobsson, LT ;
Lindblad, S ;
Lysholm, J ;
Rantapää-Dahlqvist, S ;
Saxne, T ;
Klareskog, L .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1421-1426
[4]   Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].
Baecklund, E ;
Iliadou, A ;
Askling, J ;
Ekborn, A ;
Backlin, C ;
Granath, F ;
Catrina, AT ;
Rosenquist, R ;
Feltelius, N ;
Sundström, C ;
Klareskog, L .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701
[5]  
Barton P, 2004, HEALTH TECHNOL ASSES, V8, P1
[6]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[7]  
Bathon JM, 2001, NEW ENGL J MED, V344, P240
[8]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285
[9]   Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases [J].
Botsios, C .
AUTOIMMUNITY REVIEWS, 2005, 4 (03) :162-170
[10]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
123456